ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.924,19
-1,12%
S&P 500
5.035,69
-1,57%
US Dollar vs BRL
5,1958
0,01%
Bitcoin
57.642,70
-4,88%
Brent Oil
85,055
-0,98%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Axovant Gene Therapies Ltd (AXGT)

  7. Axovant Gene Therapies Ltd (AXGT) Notícias

AXGT

Axovant Gene Therapies (AXGT)

Axovant Gene Therapies Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AXGT
DataHoraFonteTítuloCódigoCompanhia
25/04/202317:05Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202317:17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202317:14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AXGTAxovant Gene Therapies Ltd
12/04/202309:52Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202317:08Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202317:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/03/202307:03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
21/02/202318:06Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202308:47Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/02/202310:53Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202318:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:AXGTAxovant Gene Therapies Ltd
09/02/202308:01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/06/202208:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202219:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/10/202118:19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/08/202117:15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
16/12/202009:00Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AXGTAxovant Gene Therapies Ltd
02/12/202009:00GlobeNewswire Inc.Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangl...NASDAQ:AXGTAxovant Gene Therapies Ltd
20/11/202008:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AXGTAxovant Gene Therapies Ltd
19/11/202010:00GlobeNewswire Inc.Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific AdvisorNASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202009:06Edgar (US Regulatory)Registration of Securities of Successor Issuers (8-k12g3)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202009:00GlobeNewswire Inc.Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202019:11Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202009:00GlobeNewswire Inc.Axovant Gene Therapies Announces Name Change to Sio Gene TherapiesNASDAQ:AXGTAxovant Gene Therapies Ltd
09/11/202009:00GlobeNewswire Inc.Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff DiseasesNASDAQ:AXGTAxovant Gene Therapies Ltd
29/10/202017:01GlobeNewswire Inc.Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 202...NASDAQ:AXGTAxovant Gene Therapies Ltd
22/10/202008:00GlobeNewswire Inc.Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
13/10/202008:00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff DiseaseNASDAQ:AXGTAxovant Gene Therapies Ltd
09/10/202008:00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 GangliosidosisNASDAQ:AXGTAxovant Gene Therapies Ltd
08/10/202008:00GlobeNewswire Inc.Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial OfficerNASDAQ:AXGTAxovant Gene Therapies Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:AXGT

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
TECN3
TECHNOS ON
BOV
BLAU3
Blau Farmaceutica ON
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados